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Abstract
Background: To evaluate the effect of lifestyle modifications on metabolic syndrome (MetS) as assessed by its
resolution and improved values for its components.
Methods: This was a systematic review and meta-analysis. Searches were performed of MEDLINE and the Cochrane
Database from January 1966 to October 2011 to identify randomized controlled trials (RCTs) related to the study
objective. The included studies were RCTs restricted to the English language, with a follow-up period of 6 months
or more, which reported overall resolution of MetS or values of MetS components (fasting blood glucose, waist
circumference, high-density lipoprotein (HDL), triglycerides, and systolic and diastolic blood pressure (SBP, DBP)).
Two investigators independently assessed study eligibility. The effect sizes were the relative proportion of patients
with resolved MetS and mean differences in MetS component values from baseline to 1-year follow-up in a
lifestyle-modification intervention (LMI) group versus a control (conventional lifestyle education or no treatment)
group. Meta-analyses were conducted using a random-effects model.
Results: Eleven interventions in eight RCTs were used for the meta-analyses. The relative proportion of patients
with resolved MetS in the intervention group was approximately 2.0 (95% CI 1.5 to 2.7) times greater in the
intervention group compared with the control group (7 interventions, n = 2.839). LMI (5 interventions, n = 748)
significantly reduced mean values for SBP by -6.4 mmHg (95% CI -9.7 to -3.2), DBP by -3.3 mmHg (95% CI -5.2 to
-1.4), triglycerides by -12.0 mg/dl (95% CI -22.2 to -1.7), waist circumference by -2.7 cm (95% CI -4.6 to -0.9), and
fasting blood glucose by -11.5 mg/dl (95% CI -22.4 to -0.6) (5 interventions), but reductions were not significant for
HDL (1.3 mg/dl; 95% CI -0.6 to 3.1).
Conclusions: The LMI was effective in resolving MetS and reducing the severity of related abnormalities (fasting
blood glucose, waist circumference, SBP and DBP, and triglycerides) in subjects with MetS.
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Background
Metabolic syndrome (MetS), also called ‘insulin resis-
tance syndrome’ [1], ‘death quartet’ [2], or ‘syndrome X’
[3], places an individual at risk for type 2 diabetes (T2D)
and cardiovascular disease (CVD) [4]. MetS is becoming
a worldwide epidemic as a result of the increased preva-
lence of obesity and a sedentary lifestyle, and the preva-
lence of MetS in the adult population is relatively high.
Four elements comprising MetS have been identified:
central obesity, dyslipoproteinemia (increased triglycer-
ides and reduced high-density lipoprotein (HDL) choles-
terol), hypertension, and glucose intolerance; however,
the definitions used vary somewhat between ethnic
groups. Namely, the National Cholesterol Education Pro-
gram Adult Treatment Panel (ATP) III [5] defined MetS
as the presence of three or more of the following condi-
tions: waist circumference greater than 102 cm in men
and greater than 88 cm in women (for Japanese, greater
than 85 cm in men and greater than 90 cm in women),
triglyceride level of at least 150 mg/dl, HDL level less
than 40 mg/dl in men and less than 50 mg/dl in women,
systolic/diastolic blood pressure (SBP/DBP) 130/85 mm
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Hg or higher, and fasting blood glucose level 110 mg/dl
or higher. The definitions put forward by the European
Group for the Study of Insulin Resistance [6] and the
World Health Organization [7] are somewhat different
from those presented by the ATP III.
The ATP III placed major emphasis on therapeutic life-
style changes as an essential strategy for clinical manage-
ment of people at risk for CVD [8]. In an earlier study, we
examined the effect of lifestyle modification on patients at
high risk of type 2 diabetes and found that a lifestyle modi-
fication program was effective in reducing both 2-hour
plasma glucose levels and the incidence rate, thus, lifestyle
education may be a useful tool in preventing T2D [9].
Changing dietary and exercise behavior may lead to a heal-
thier waistline measurement and body mass index (BMI),
improved values for HDL and triglyceride, lower BP, and
lower blood glucose. Lifestyle change must be an integral
part of risk reduction therapy for MetS and for T2D. How-
ever, these recommendations were mainly focused on
patients who had specific risk factors for developing MetS,
such as obesity, diabetes, high blood pressure, coronary
heart disease (CHD), and other risk factors. One reason
for this is the variation in the definition of MetS.
The effects of lifestyle modification for patients with
MetS are still unknown. To assess the effects of a dietary-
based lifestyle modification intervention (LMI; incorporat-
ing lifestyle modifications such as ‘diet’ and ‘diet and exer-
cise’) on the reduction of MetS and the improvement in
values for MetS components in subjects with this syn-
drome, we conducted a systematic review of randomized
controlled trials (RCTs) that examined lifestyle interven-
tions for MetS. We also performed a meta-analysis of the
data obtained and conducted several sensitivity analyses.
The results of our analyses revealed important information
for the treatment of T2D as well.
Methods
Study design and search strategy
The study design was a systematic review of the pub-
lished literature and a meta-analysis of data from each
selected study. The study question was whether an LMI
program improved the overall resolution of MetS or
values of MetS components in adults with MetS, com-
pared with conventional education. A single investigator
(KY) searched MEDLINE and the Cochrane Database
(data from January 1966 to October 2011) to identify
relevant literature restricted to the English language. Free
text terms, MeSH terms, and combinations of words
were used for search terms. For instance, ‘metabolic syn-
drome’, ‘exercise’, ‘physical fitness’, ‘nutrition’, ‘diet’, ‘pre-
vention’, ‘adults’, and ‘RCT’ were used as search terms
(for full details of search strategies, see Additional file 1,
Table S1).
Study selection
RCTs that followed up patients for 6 months or more
were included. Randomization of individuals or clusters
of individuals were accepted. Reports of lifestyle inter-
vention (combined diet and exercise) or dietary educa-
tion alone were selected. Specific dietary programs, such
as the Mediterranean diet, were treated as dietary inter-
ventions. Control interventions were the conventional
education usually given to patients with MetS or no
treatment. In the systematic review process, if results of
one study were reported in more than one publication,
we selected the report for the analysis that included the
most information at 1 year, and information on the life-
style and dietary interventions was extracted. Further-
more, if a study reported intervention results for
patients with MetS by a stratified analysis, we treated
that part of the report as a RCT study. When a trial had
3 or more arms, we treated each arm independently.
Two investigators (KY, TT) independently assessed
eligibility.
Data extraction and risk of bias in individual studies
Participants in the examined studies were adults who
were diagnosed with MetS according to the ATP III
definitions or to other guidelines. To reduce the risks
related to MetS, it is necessary that the state of MetS
itself be resolved. In selecting studies for this meta-
analysis, two main outcome measures from the
described intervention were primarily considered.
These were the proportion of patients with resolution
of MetS and the reduction in the mean values of the
major components of MetS (waist circumference, HDL,
triglyceride, SBP, DBP, and fasting blood glucose) from
baseline to the end of study follow-up (6 months or
more; most studies were 1 year). The relative propor-
tion of patients with resolved MetS (RR) was examined
primarily to assess the strength of the effects in an
LMI group compared with a control group (relative
risk was equal to the proportion of patients with MetS
in the intervention group divided by the proportion of
patients in the control group (RR = Pi/Pc)). If Pc was
0, then 0.5 was added for all the cells in the calculation
of RR. The differences in the means of the component
measures between the two groups were the other effect
sizes of this study. The difference was equal to di - dc,
where di and dc were mean differences from baseline
to endpoint in the measurement between the LMI and
control groups. When the standard deviation (SD) of
the difference from baseline to endpoint was not given
in the literature, it was calculated using the following
formula:
SD2 = SD2pre + SD2post − 2rSDpreSDpost,
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where SDpre is the SD of the baseline value, SDpost is
the endpoint value, and r is the correlation between the
baseline and endpoint groups.
Because no study reported a value for r, and its true
value was unknown, we consulted our past study data
[9] and used r = 0.5. Sensitivity analyses were also car-
ried out, using r = 0.3 and r = 0.7. If the 95% confidence
interval (95% CI) was shown instead of SD, SD was cal-
culated using the formula:
SD = (
√
n) (95%Clupper − 95%Cllower)/4,
where n denotes the sample size of a group.
Two investigators (KY, TT) independently extracted
the data, and disagreements were resolved by consensus.
Eight studies were selected for systematic review and
meta-analysis, after agreement was reached by both
assessors. Studies were mainly assessed for the elements
of allocation concealment, blinding, and loss to follow-
up, which were listed as an elements of risk of bias table
following a Cochrane review [10]. The Preferred Report-
ing Items for Systematic Reviews and Meta-Analyses
(PRISMA) standard [11] was followed during all phases
of the design and implementation of the present
analysis.
Statistical analysis
Overall estimates were examined using the random-
effects model (DerSimonian-Laird method) [12]), the
Bayesian model of Warn et al.[13] with non-informative
priors, and a fixed-effects model (general variance-based
method). A c2 test was used to assess heterogeneity
between trials. A cumulative meta-analysis by the ran-
dom-effects model was performed to determine at
which point sufficient evidence was available to shown a
beneficial effect of LMI. Publication bias was visually
examined using a funnel plot. The estimates from the
random-effects model were plotted. Because 1) the
fixed-effects model is useful under homogeneous condi-
tions, 2) the types of LMIs and duration of follow-up
durations varied between studies, and 3) the power of
statistical tests of homogeneity is low, we planned to use
the random-effects model as the primary method, irre-
spective of the test of heterogeneity. S-plus [14] was
used for estimation of the random-effects model and the
fixed-effects model, and OpenBUGS [15] was used for
the Bayesian model (number of chains = 2, burn-in sam-
ple = 10,000, number of Gibbs sampling = 10,000). Sig-
nificance was set at P = 0.05 (two-tailed).
Results
The procedure for the systematic review was carried out inn
accordance with the PRISMA guidelines [11] (Figure 1).
Table 1 summarizes basic information on each trial. Eleven
interventions (eight RCTs) in total were assessed [16-23];
one RCT had two types of dietary interventions (that is, dif-
ferent diet programs or ‘diet and exercise’), thus each inter-
vention was treated as an independent intervention. Eight
interventions (six RCTs) [16-21] were used for the analysis
of relative proportion of patients with resolved MetS, and
seven interventions (five RCTs) [18,20-23] were used for
the analyses of MetS components.
Types of intervention
The LMIs in the selected studies varied to some degree,
and can be divided into those using dietary intervention
only, and those using diet plus exercise.
Dietary intervention
Several types of dietary education interventions were
used in four studies [17,20,21,23], as follows.
The first study used a Mediterranean-style diet with
detailed advice about how to increase daily consumption
of whole grains, fruits, vegetables, nuts, and olive oil,
while the control subjects were required to follow a pru-
dent diet (50% to 60% carbohydrates, 15% to 20% pro-
teins, 30% total fat) [21].
The intervention in the second study consisted of two
high-fat Mediterranean diets with virgin olive oil or
nuts, with a low-fat diet as the control [17].
In another study, two types of diet were also used as
an intervention [20]. One diet was the DASH (Dietary
Approaches to Stop Hypertension) diet, which provided
500 kcal less than the subject’s daily caloric needs, with
increased consumption of fruit, vegetables, and low-fat
dairy products, and decreased consumption of saturated
fat, total fat, and cholesterol. This diet included more
whole grains and fewer refined grains, sweets, and red
meat than in usual diet. The other diet was aimed at
weight reduction through provision of general informa-
tion provided both orally and in writing about healthy
food choices and recommendations to consume 500
kcal less per day than the caloric needs, based on
weight. Control subjects were asked not to make any
changes in their normal daily life.
The fourth study used two dietary interventions: a
low-fat, complex carbohydrate diet (LF-CC) or a low-fat,
simple carbohydrate diet (LF-SC) for 6 months [23].
Control subjects were advised to maintain fat intake at
habitual amounts (35% to 40% of energy.)
Diet and lifestyle modification
In the remaining four RCTs, dietary education was con-
ducted along with exercise, including exercise
[16,18,19,22].
In the first study, lifestyle modification with an indivi-
dually prescribed diet was given in line with standard
guidelines, and advice on exercise was individualized,
mainly by suggesting moderate-intensity activity, such as
brisk walks for at least 150 minutes/week [16]. Control
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subjects were provided with general information empha-
sizing the importance of a healthy lifestyle from their
family physicians, who gave advice according to their
usual clinical practice.
In the second study, the LMI was to encourage people
to make healthy lifestyle choices. Participants in the
intervention group were given detailed and individua-
lized dietary and exercise counseling. Sessions for super-
vised and individually tailored progressive circuit-type
resistance training at moderate intensity were recom-
mended twice a week, and offered free of charge by
three of the five study centers participating in this
research [18]. In addition, because that study reported
only the proportions of patients with MetS and those
with resolved MetS, the number of patients with
resolved MetS was calculated by multiplying the total
number of patients and the proportions of resolved and
unresolved MetS. Meanwhile, control subjects were
given general information about healthy food choices,
physical activity, and weight loss at baseline, but with no
individualized counseling.
The third of these studies was a three-group randomi-
zation trial [19]. In the first group, participants were
given an intensive program of lifestyle intervention with
the goals of achieving and maintaining a weight reduc-
tion of at least 7% of body weight through a healthy
low-calorie, low-fat diet, and were instructed to engage
in physical activity of moderate intensity, such as brisk
walking, for at least 150 minutes per week [19]. Partici-
pants in the second group were given standard lifestyle
recommendations plus a placebo, and participants in the
third group were given standard lifestyle recommenda-
tions and metformin. We did not include the third
group in the present analysis. Patients were given weekly
Figure 1 Systematic review flow diagram.
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Table 1 Characteristics of included randomized clinical trials.a

















46 M/F LF-SC 0.5 - - - 0.0 (2.02) -13.0 (5.56) -0.6 (4.29) 50.7 (19.95) 0.5 (2.42)
UK, CARMEN
trial [23]
46 ≥3 MetS risk
factors
46 M/F LF-CC 0.5 - - - -4.0 (2.94) -15.0 (6.33) -4.2 (4.29) 0.0 (16.62) -1.5 (2.42)
USA [22] 53 Syndrome X >29 M/F EX+WL 0.5 - - -8.0 (4.84) - -6.0 (4.17) -9.0 (2.08) -17.0 (64.11) 4.0 (4.26)
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55 M/F L 1 15% = 26/
177
27% = 49/184 - - - - - -
ATP III = The National Cholesterol Education Program’s Adult Treatment Panel III; CARMEN = Carbohydrate Ratio Management in European National diets; DASH = The Dietary Approaches to Stop Hypertension; DBP
= diastolic blood pressure; DPPRG = Diabetes Prevention Program Research Group; DPS = Diabetes Prevention Study; EX+WL = dietary and behavior modification for weight loss plus exercise; FBG = fasting blood
glucose; HDL = high-density lipoprotein; hs-CRP+2 = 2 components of metabolic syndrome plus high-sensitivity CRP serum values ≥3 mg/L; L = lifestyle recommendation; LF-CC = low-fat; high-complex-carbohydrate
diet; LF-SC = low-fat; high-simple-carbohydrate diet; Med = Mediterranean; MetS = metabolic syndrome; PREDIMED = Prevención con Dieta Mediterránea; SBP = systolic blood pressure; TG = triglycerides; VOO =
virgin olive oil; WR = weight-reducing diet; WR+EX = weight-reducing diet plus exercise.
aStudies [20-26] were used for the meta-analysis of the metabolic syndrome components.
bSD was calculated using 95% confidence interval for references [18,20,21].




















advice on nutrition for the first 4 weeks, and subse-
quently every 2 weeks. Caloric intake was restricted
using a middle-European balanced diet (~50% carbohy-
drates, ~30% protein, 20 g to 60 g fat/day supplemented
by vitamins and minerals).
Finally, in the fourth study, participants exercised
three to four times per week using an identical protocol
and participated in a weight-management program in
small groups of three to four members [22]. The
weight-management program was a behavioral interven-
tion based on a manual, which focused on five elements:
lifestyle, exercise, attitudes, relationships, and nutrition.
The primary goal of the intervention was a weight loss
of 0.5 to 1 kg per week, achieved gradually by decreas-
ing calorie and fat intake through permanent lifestyle
changes. Initial dietary goals were set at approximately
1200 kcal for women and 1,500 kcal for men, with
about 15% to 20% of calories coming from fat. Control
subjects were asked to maintain their usual dietary and
exercise habits for 6 months [22].
Risk of bias
We carried out a summary assessment of risk of bias for
the included studies (see Additional file 2, Figure S1).
All study designs were RCTs and similar at baseline;
however, allocation concealment was unclear in all
except in three studies [18,20,21]. Blinding of partici-
pants and researcher was also unclear in 6 studies
[16,19,22,23] but blinding of outcome assessment was
shown in most of the papers. For the outcome value,
the number of patients was calculated from the propor-
tions in two studies [17,19]. The response rates of two
studies [22,23] were less than 80%, and the proportion
of gender varied. Because six of the seven items assessed
were unclear in these two studies, the subgroup analysis
was conducted excluding these two studies.
Relative proportion of patients with resolved MetS
Excluding one [18] of the eight studies, the analysis for
RR (n = 2839) showed evidence of heterogeneity
between studies (P < 0.001). RR was 2.0 (95% CI 1.5 to
2.7) by the random-effects model for seven interven-
tions, and the other models showed similar values
(Table 2). When the analysis was repeated with all eight
studies (including the previous excluded study [18]) the
results were similar. Figure 2 shows a forest plot for RR
with the 95% CIs (shown by lines extending from the
quadrangular symbols) of each study and overall esti-
mates by several models (the range of 95% CIs of the
overall estimates for several models are shown by a
solid line between diamond symbols). All results indi-
cated that the RR was greater in the LMI groups (med-
ian of the duration of the follow-up, 2 years) than in the
control groups. Because only a few studies were
included in the analysis, our planned subgroup analysis
was not conducted. A funnel plot showing sample size
against effect size suggested little influence from publi-
cation bias on the effect size (not shown), but this analy-
sis was severely underpowered, with only eight
interventions, and so the conclusions about publication
bias were therefore unreliable.
Difference in means for the components of MetS
Overall, the LMI (median 1 year) produced significantly
reduced mean values (7 interventions, n = 710) com-
pared with the control intervention as determined by
the random-effects model. The values were 11.5 mg/dl
(95% CI -22.4 to -0.6) for fasting blood glucose (5 inter-
ventions), -2.7 cm (95% CI -4.6 to -0.9) for waist cir-
cumference (6 interventions), -6.4 mmHg (95% CI -9.7
to -3.2) for SBP, -3.3 mmHg (95% CI -5.2 to -1.4) for
DBP, and -12.0 mg/dl: 95% CI -22.2 to -1.7) for trigly-
cerides. The reduced mean values were not significant
for HDL (1.3 mg/dl; 95% CI -0.6 to 3.1). Estimates for
the sensitivity analyses for r = 0.3 and r = 0.7 were not
greatly different from that for r = 0.5 (Table 2). The
results of the subgroup analyses using four interventions
denoted similar significance levels.
Discussion
This meta-analysis provides evidence of the efficacy of
an LMI in resolving the proportions of patients with
MetS in comparison with conventional education. The
proportion of patients with resolved MetS in the inter-
vention group was approximately two times higher in
the intervention group than in the control group. Values
for five of the six components of MetS (excluding HDL)
were significantly reduced in the LMI groups compared
with their control groups. Several sensitivity analyses
supported these results.
The major goals for subjects in the intensive LMI
groups included achieving and maintaining a weight
reduction through diet and moderate-intensity physical
activity. Most of the control group received only stan-
dard lifestyle suggestions. The results of the previous
meta-analyses for exercise performed by Carroll and
Dudfield [24] were 1.8 mg/dl (95% CI 1.1 to 2.6 mg/dl)
for HDL (20 RCTs) and -19 mg/dl (95% CI -26 to -13
mg/dl) for triglycerides (19 RCTs). Because the effect
size changes between the study groups were homoge-
neous, the authors used a fixed-effects model (weighted
mean difference method) for the estimation of an overall
effect size. The pooled estimate of the effect size was
small but significant for both HDL and triglyceride. Our
meta-analysis suggested an effect size of 1.3 mg/dl (95%
CI -0.6 to 3.1 mg/dl) for HDL and -12 mg/dl (95% CI
-22 to -2 mg/dl) for triglyceride by the random-effects
model, and 2.9 mg/dl (95% CI 2.5 to 3.3 mg/dl) and -19
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mg/dl (95% CI -20 to -17 mg/dl), respectively, by the
fixed-effects model. The differences between the two
meta-analyses were the type of intervention and study
duration. Namely, in our analyses, the LMIs comprised
‘exercise and diet’ or ‘diet only’, whereas the in the stu-
dies assessed by Carroll and Dudfield, the LMI was
‘exercise’. Our meta-analysis required a duration of ‘6
months or over, median 1 yr’, which was longer than
the ‘12 to 52 weeks’ required in the meta-analysis by
Carroll and Dudfield. Although we cannot deny possible
bias, dietary lifestyle intervention is possibly a more
effective method than exercise intervention.
A previous meta-analysis of the Mediterranean diet
using epidemiological studies [25] found a beneficial
effect of the Mediterranean diet on individual compo-
nents of MetS, including waist circumference, HDL, tri-
glycerides, systolic and DBP, and glucose metabolism.
However, it should be noted that in that meta-analysis
of the Mediterranean diet, the subjects included high-
risk participants. In our analysis, we used only RCTs for
patients with MetS, and used several models for ana-
lyses, such as sensitivity analyses, because of the hetero-
geneity of the studies. Nevertheless, our results
suggested that the Mediterranean diet and general life-
style modification, including dietary education, were
beneficial.
Strengths and limitations
To our knowledge, this is the first study employing a
meta-analysis of RCT s that has examined the effects of
lifestyle modification for individuals with MetS. How-
ever, the educational training used was not uniform
across the studies. The strengths of our study were that
it analyzed only RCTs and assessed the magnitude of
the effects primarily according to the relative proportion
of patients with resolved MetS, and by the difference in
mean changes in individual MetS components. The
results suggest that lifestyle modification was more likely
than conventional education to result in resolution of
MetS. Although we found a weak tendency toward
Table 2 Comparison of the results of the random-effects meta-analysis (relative proportion of patients with resolved
metabolic syndrome (MetS) and difference in mean)
Total (95% CI) Model Point Estimate d 95% CI (lower to upper)
The ratio of proportions patients with resolved MetS (7 interventions)a Random 2.0 1.5 to 2.7
Bayesian 2.4 1.5 to 5.5
Fixed 1.9 1.7 to 2.2
Mean difference (7 interventions) b
Fasting blood glucose, mg/dl Random c -11.5 -22.4 to -0.6
(5 interventions) Bayesian -5.1 -8.6 to -0.9
Fixed -18.7 -20.4 to -17.0
Waist circumference, cm
(6 interventions)
Random c -2.7 -4.6 to -0.9
Bayesian -2.6 -4.6 to -0.6
Fixed -2.0 -2.1 to -1.9
SBP, mmHg Random c -6.4 -9.7 to -3.2
Bayesian -7.9 -12.3 to -3.9
Fixed -3.1 -3.6 to -2.7
DBP, mmHg Random c -3.3 -5.2 to -1.4
Bayesian -3.5 -6.2 to -0.97
Fixed -2.0 -2.3 to -1.8
Triglyceride, mg/dl Random c -12.0 -22.2 to -1.7
Bayesian -4.8 -28.1 to 18.8
Fixed -18.7 -20.4 to -17.0
HDL, mg/dl Random c 1.3 -0.6 to 3.1
Bayesian 0.7 -2.4 to 3.8
Fixed 2.9 2.5 to 3.3
a8 interventions including estimated data denote 2.0 (1.5 to 2.5) for the random-effects, 2.7 (1.6 to 5.8) for the Bayesian, and 1.9 (1.7 to 2.2) for the fixed model,
respectively. Number of subjects that could have resolved MetS = 1400 (intervention) and 1439 (control), 2839 in total. Proportions of resolved patients = 35.0%
(intervention) and 17.6% (control). bNumber of subjects for mean difference = 379 (intervention) and 369 (control), 748 in total. c Random = DerSimonian-Laird
method, 95% CI = 95% confidence interval.
d The estimates by the sensitivity analyses using r = 0.3 and r = 0.7 were the same with r = 0.5 for fasting blood glucose and waist circumference, and it varied
for SBP (-7.1, -6.4), DBP (-3.6, -2.9), triglycerides (-12.7, -11.5), and HDL (0.9, 1.6). The estimates by the subgroup analyses using 4 interventions [18,20,21] (random-
effects model) denote -3.1 (-5.3 to -0.9) for fasting blood glucose, -3.1 (-5.2 to -1.0) for waist circumference, -5.1 (-8.8 to -1.9) for SBP, -2.3 (-3.3, -1.3) for DBP, -11.5
(-22.4 to -0.6) for triglyceride, and 1.5 (-0.6 to 3.47) for HDL.
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reduction in fasting blood glucose, we consider that fast-
ing blood glucose is not a sensitive index for glucose
intolerance. In our experience from a previous study on
the effects of lifestyle modification in preventing T2D, a
significant effect was shown in the level of plasma glu-
cose 2 hours after an oral glucose load of 75 g, but such
an effect was not shown for fasting blood glucose [26].
To confirm whether fasting blood glucose level is a
good index as the component for glucose intolerance,
further evidence is required.
Certain limitations of this study should be considered.
The first is publication bias. From the visual observation
of sample size on effect size (figure not shown), the
result did not seem to be greatly affected by sample size.
We performed electronic searches and a hand search.
However, this study used a small number of studies
with high heterogeneity, thus a funnel-plot assessment
may be not appropriate to examine the publication bias.
This analysis was confined to English-language articles,
which could also introduce publication bias. However,
Moher et al.[11] found that language-restricted meta-
analyses overestimated the treatment effect by only 2%
on average compared with language-inclusive meta-ana-
lyses, although the language-inclusive meta-analyses
were more precise. Furthermore, we included only
RCTs in the present meta-analysis, which could also
introduce bias. However, considering that the quality of
studies of lifestyle and dietary education may be affected
by many confounding biases, these limitations may be
acceptable. Publication bias is always a concern in meta-
analyses, and although it may be small, we cannot deny
the possibility of such bias. We assessed the studies
based on the information reported in the papers mainly
for the elements of risk of bias table in the relevant
Cochrane review [10]. Although the power was low, the
significance levels in the subgroup analyses were similar
to those of the primary analyses.
A second limitation relates to study duration. We col-
lected data only from studies with a follow-up period
extending for more than 6 months. This may be accep-
table, however, because earlier assessments could be
biased as a result of changes made only because subjects
were conscious of being studied. The duration of follow-
up in the included studies was 6 months [20,22,23], 1
year [16,18], 2 years [21], and 3 years [17,19]. In the
prevention and resolution of MetS, maintaining long-
term control is likely to be warranted [27].
A third limitation is the variability in the LMIs. Life-
style modification was not uniform, and varied depend-
ing social circumstances, therefore heterogeneity might
RR 
Figure 2 Forest plot of the relative proportion of patients with resolved metabolic syndrome (MetS) with 95% CI for each study and
overall for several models (eight interventions). The solid lines extending from the square symbols are 95% CIs of individual studies in the
forest plot. Dotted lines extending from the circular symbols are 95% CIs of the cumulative meta-analysis in the forest plot.
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be accepted. In most trials, the control diet was the sub-
ject’s usual diet, whereas the lifestyle modification
included some special diets such as the Mediterranean
diet [17,21] and DASH diet [20], among others, and
most of the studies included recommendations for exer-
cise. Because of this heterogeneity, we used the random-
effects model as the primary analysis. Although the
quality and content of lifestyle modification varied, the
results indicated that it was effective. Because the num-
ber of studies was too small to perform difference-by-
subgroup analyses, we could not conduct these analyses
by intervention styles. Furthermore, even though our
search method used systematic review and added hand
searching, we could have inadvertently missed eligible
studies. The results should be interpreted carefully, con-
sidering the risk of bias across studies.
Implications for practice and research
Many of the changes noted in this review were signifi-
cant and improvements were observed, but the absolute
values were small in terms of magnitude. It should be
emphasized that these outcomes measured are surrogate
outcomes. Important patient outcomes such as inci-
dence of CHD and T2D should be investigated in future
studies.
As the results of the present study show, there is a
need for adequate assessment of lifestyle modification
for resolving MetS. Future research evaluating lifestyle
modification with and without weight loss, lifestyle
modification of diet versus aerobic exercise versus com-
bination therapies, lifestyle modification versus medi-
cine, and other comparisons is needed to clarify which
aspects and what degree of lifestyle modification are
best to resolve MetS.
Conclusions
This meta-analysis further strengthens the evidence that
long-term regular lifestyle modification, including diet-
ary modification only, reduces the prevalence of MetS
and abnormalities associated with MetS, and may be a
useful tool in reducing the future occurrence of MetS.
Additional material
Additional file 1: Table S1. Search strategy used for MEDLINE.
Additional file 2: Figure S1. Risk of bias assessment for studies in a
Cochrane review.
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